Ads
related to: monoclonal gammopathy treatment drugs- Symptom & Condition Info
Understand The Causes & Symptoms of
gMG. Get Condition Information.
- Find An Infusion Center
Learn About Treatment And
Locate The Nearest Infusion Center.
- Patient Resources
Download Brochures. Connect With
The gMG Community & Support Groups.
- Access Savings Info
Eligible Patients May Qualify For
Financial Assistance. Learn More.
- gMG Glossary
Read About Helpful Terms Pertaining
To Generalized Myasthenia Gravis.
- Sign Up For Updates
Get Resources, Treatment Support
& Tools To Talk To Your Doctor.
- Symptom & Condition Info
Search results
Results From The WOW.Com Content Network
This list of over 500 monoclonal antibodies includes approved and investigational drugs as well as drugs that have been withdrawn from market; consequently, the column Use does not necessarily indicate clinical usage. See the list of FDA-approved therapeutic monoclonal antibodies in the monoclonal antibody therapy page.
Monoclonal gammopathy, also known as paraproteinemia, is the presence of excessive amounts of myeloma protein or monoclonal gamma globulin in the blood. It is usually due to an underlying immunoproliferative disorder or hematologic neoplasms , especially multiple myeloma .
Monoclonal gammopathy of undetermined significance (MGUS) is a plasma cell dyscrasia in which plasma cells or other types of antibody-producing cells secrete a myeloma protein, i.e. an abnormal antibody, into the blood; this abnormal protein is usually found during standard laboratory blood or urine tests.
The advantage of active monoclonal antibody therapy is the fact that the immune system will produce antibodies long-term, with only a short-term drug administration to induce this response. However, the immune response to certain antigens may be inadequate, especially in the elderly.
Bortezomib can also be given before and after an autologous stem cell transplant (ASCT) with high dose of the chemotherapy medication mephalan given before ASCT to eradicate the monoclonal gammopathy prior to transplant and prevent recurrence. [1] Alternative treatment options include immunomodulatory drugs such as thalidomide or lenalidomide. [1]
The US Food and Drug Administration (FDA) approved mogamulizumab in August 2018, [15] for the treatment of relapsed or refractory mycosis fungoides and Sézary disease. [8] Mogamulizumab was approved in Japan in 2012, for the treatment of relapsed or refractory CCR4+ adult T-cell leukemia/lymphoma and in 2014, for relapsed or refractory CCR4 ...